2026-526179-49-00RecruitingPhase 4
Non-inferiority of surgical treatment of cartilage defects of the knee with autologous minced cartilage implantation (AMCI) and matrix-asscociated autologous chondrocyte implantation with respect to KOOS at 24 months (M ACI) - MinCaRCT
Medical Center - University Of Freiburg8 sites in 1 country166 target enrollmentStarted: June 30, 2026Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 4
- Status
- Recruiting
- Sponsor
- Enrollment
- 166
- Locations
- 8
- Primary Endpoint
- The primary efficacy endpoint is the KOOS5 (composite Knee injury and Osteoarthritis Outcome Score) at 24 months after randomisation
Study Overview
Brief Summary
Assessment of the mid-term efficacy of the “Minced Cartilage” procedure (AMCI) in comparison to matrix-associated autologous chondrocyte implantation (M ACI) in the treatment of large full-thickness cartilage defects of knee joints as measured in KOOS.
Eligibility Criteria
- Ages
- 18 years to 64 years (18-64 Years)
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patient with isolated ICRS grade III or IV cartilage defect of the knee with intact grade I to II corresponding cartilage joint surface
- •Defect size: 3-6 cm2 with surrounding healthy cartilage and healthy under laying bone diagnosed before enrolment by MRI or arthroscopy
- •Male or female patients aged > 18 years (and completely closed growth plate in the affected joint) to ≤ 55 years
- •established diagnosis for each of the treatment methods applied/used in the clinical trial before randomisation
Exclusion Criteria
- •Any signs of subjective and objective knee instability
- •Valgus or varus malalignment (more than 3 angular degree over the mechanical axis), which is not corrected as a parallel treatment at time of intervention
- •Partial resection of the meniscus with more than 1/3 resected or total resection in the affected knee (ipsilateral)
- •Rheumatoid arthritis, parainfectious or infectious arthritis; condition after these diseases
- •Defects on both knees at the same time or second cartilage lesion on the same knee
- •Radiological signs (X-ray, two levels) of osteoarthritis exceeding grade I on Kellgren-Lawrence Scale
- •history of and/or signs for clinically relevant organ dysfunctions
- •history of and/or signs for clinical contraindications against surgical, anesthesiologic and imaging methods applied in the clinical trial
Outcomes
Primary Outcomes
The primary efficacy endpoint is the KOOS5 (composite Knee injury and Osteoarthritis Outcome Score) at 24 months after randomisation
The primary efficacy endpoint is the KOOS5 (composite Knee injury and Osteoarthritis Outcome Score) at 24 months after randomisation
Secondary Outcomes
- Following scores and questionnaires at 3, 6, 12, 24 months after randomisation: IKDC, KOOS5, KOOS subscales (Pain, Symptoms, ADL, Sport and Recreation, QOL), Lysholm, QOL SF-12, absence from work and incidence and number of revision surgeries.
Investigators
Coordinating Investigator
Scientific
Medical Center - University Of Freiburg
Study Sites (8)
Loading locations...
Similar Trials
Not yet recruiting
Phase 2
Clinical Study to Evaluate the cartilaginous changes with medicated oil enema followed by Poultice in Knee joint PainCTRI/2025/09/094248Dr Anil S Managuli75
Not yet recruiting
Not Applicable
Comparison of Minced Cartilage Implantation Versus Microfracture for Acetabular Chondral Lesions Due to FAI (Femoro-acetabular Impingement)NCT07657871GCS Ramsay Santé pour l'Enseignement et la Recherche180
Not yet recruiting
Phase 4
Efficacy of intra-articular ozone, steroid and dextrose in improving the symptoms of osteoarthritis kneeCTRI/2025/10/096086AIIMS Kalyani63
Completed
Not Applicable
The Effect of Intraoperative Findings Shown to the Patient on Early Postoperative Clinical Outcomes in Primary Total Knee ArthroplastyPrimary GonarthrosisNCT07364812Bezmialem Vakif University80
Recruiting
Phase 4
Study to Evaluate a New Cartilage Regeneration Platform for Knee Cartilage RepairNCT07639424ROKIT Healthcare104